Wei Ding

6.1k citations

117 papers · 2.2k indexed · h-index 25

Impact in

Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment

Papers in ⓘ

Genetics 101
- Chronic Lymphocytic Leukemia Research 100
Pathology and Forensic Medicine 59
- Lymphoma Diagnosis and Treatment 57

Co-authors: Neil E. Kay (78 shared papers)Timothy G. Call (71 shared papers)Tait D. Shanafelt (51 shared papers)Susan M. Schwager (42 shared papers)Susan L. Slager (59 shared papers)Sameer A. Parikh (67 shared papers)José F. Leis (51 shared papers)Kari G. Rabe (33 shared papers)
Journals: Blood (40 papers)Journal of Clinical Oncology (7 papers)British Journal of Haematology (6 papers)American Journal of Hematology (6 papers)Blood Cancer Journal (3 papers)
Partner nations: United States China Australia

In The Last Decade

Wei Ding

109 papers receiving 2.2k citations

Peers

Countries citing papers authored by Wei Ding

Since Specialization

Citations

This map shows the geographic impact of Wei Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Ding more than expected).

Fields of papers citing papers by Wei Ding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Ding. The network helps show where Wei Ding may publish in the future.

Co-authors

The 25 scholars most cited alongside Wei Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wei Ding Line = papers co-authored together Wei Ding links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 117 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance Blood ·Antonina V. Kurtova, Kumudha Balakrishnan, Rong Chen, Wei Ding, Susanne Schnabl, Maite P. Quiroga, Mariela Sivina, William G. Wierda, Zeev Estrov, Michael J. Keating, Medhat Shehata, Ulrich Jäger, Varsha Gandhi, Neil E. Kay, William Plunkett, Jan A. Burger	2009	254
2	Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients British Journal of Haematology ·Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, Clive S. Zent, Thomas M. Habermann, Wei Ding, José F. Leis, Susan M. Schwager, Curtis A. Hanson, William R. Macon, Neil E. Kay, Susan L. Slager, Tait D. Shanafelt	2013	155
3	Platelet-derived growth factor (PDGF)–PDGF receptor interaction activates bone marrow–derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch Blood ·Wei Ding, Traci R. Knox, Renee C. Tschumper, Wenting Wu, Susan M. Schwager, Justin C. Boysen, Diane F. Jelinek, Neil E. Kay	2010	101
4	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) Leukemia & lymphoma ·Tait D. Shanafelt, Sameer A. Parikh, Peter A. Noseworthy, Valentin Goede, Kari G. Chaffee, Jasmin Bahlo, Timothy G. Call, Susan M. Schwager, Wei Ding, Barbara Eichhorst, Kirsten Fischer, José F. Leis, Asher Chanan‐Khan, Michael Hallek, Susan L. Slager, Neil E. Kay	2016	94
5	Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels Journal of Oncology Practice ·Tait D. Shanafelt, Bijan J. Borah, Heidi D. Finnes, Kari G. Chaffee, Wei Ding, José F. Leis, Asher Chanan‐Khan, Sameer A. Parikh, Susan L. Slager, Neil E. Kay, Tim G. Call	2015	79
6	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma British Journal of Haematology ·Clive S. Zent, Wei Ding, Susan M. Schwager, Megan S. Reinalda, James D. Hoyer, Diane F. Jelinek, Renee C. Tschumper, Deborah A. Bowen, Timothy G. Call, Tait D. Shanafelt, Neil E. Kay, Susan L. Slager	2008	78
7	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center Haematologica ·Yucai Wang, Marcella Tschautscher, Kari G. Rabe, Timothy G. Call, José F. Leis, Saad S. Kenderian, Neil E. Kay, Eli Muchtar, Daniel L. Van Dyke, Amber B. Koehler, Susan M. Schwager, Susan L. Slager, Sameer A. Parikh, Wei Ding	2019	76
8	The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells PLoS ONE ·Stefania Fiorcari, Wells S. Brown, Bradley W. McIntyre, Zeev Estrov, Rossana Maffei, Susan O’Brien, Mariela Sivina, Julia Hoellenriegel, William G. Wierda, Michael J. Keating, Wei Ding, Neil E. Kay, Brian J. Lannutti, Roberto Marasca, Jan A. Burger	2013	75
9	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes Cancer ·Sameer A. Parikh, José F. Leis, Kari G. Chaffee, Timothy G. Call, Curtis A. Hanson, Wei Ding, Asher Chanan‐Khan, Deborah A. Bowen, Michael Conte, Susan M. Schwager, Susan L. Slager, Daniel L. Van Dyke, Diane F. Jelinek, Neil E. Kay, Tait D. Shanafelt	2015	73
10	Bi‐directional activation between mesenchymal stem cells and CLL B‐cells: implication for CLL disease progression British Journal of Haematology ·Wei Ding, Grzegorz S. Nowakowski, Traci R. Knox, Justin C. Boysen, Mary Maas, Susan M. Schwager, Wenting Wu, Linda Wellik, Allan B. Dietz, Asish K. Ghosh, Charla Secreto, Kay L. Medina, Tait D. Shanafelt, Clive S. Zent, Timothy G. Call, Neil E. Kay	2009	68
11	Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novoHodgkin lymphoma American Journal of Hematology ·Sameer A. Parikh, Thomas M. Habermann, Kari G. Chaffee, Timothy G. Call, Wei Ding, José F. Leis, William R. Macon, Susan M. Schwager, Kay M. Ristow, Luis F. Porrata, Neil E. Kay, Susan L. Slager, Tait D. Shanafelt	2015	60
12	Chronic lymphocytic leukemia in young (<= 55 years) patients: a comprehensive analysis of prognostic factors and outcomes Haematologica ·Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, Susan M. Schwager, Daniel A. Bowen, Michael Conte, Diane F. Jelinek, Susan L. Slager, Tait D. Shanafelt	2013	52
13	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis Leukemia & lymphoma ·Clive S. Zent, Wei Ding, Megan S. Reinalda, Susan M. Schwager, James D. Hoyer, Deborah A. Bowen, Diane F. Jelinek, Renee C. Tschumper, Timothy G. Call, Tait D. Shanafelt, Neil E. Kay, Susan L. Slager	2009	52
14	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT) The American Journal of Surgical Pathology ·Rong He, Wei Ding, David S. Viswanatha, Dong Chen, Min Shi, Daniel Van Dyke, Shulan Tian, Linda N. Dao, Sameer A. Parikh, Tait D. Shanafelt, Timothy G. Call, Stephen M. Ansell, José F. Leis, Ming Mai, Curtis A. Hanson, Karen L. Rech	2018	51
15	First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101) Blood ·John F. Seymour, Chan Y. Cheah, Ricardo Parrondo, Meghan C. Thompson, Don A. Stevens, Masa Lasica, Michael Wang, Abhijeet Kumar, Judith Trotman, Maan Alwan, Wei Ding, Kunthel By, Bilal Tariq, Xiangmei Chen, Shannon Fabre, Jason C. Paik, Amit Agarwal, Constantine S. Tam	2023	45
16	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice Leukemia & lymphoma ·Paul J. Hampel, Wei Ding, Timothy G. Call, Kari G. Rabe, Saad S. Kenderian, Thomas E. Witzig, Eli Muchtar, José F. Leis, Asher Chanan‐Khan, Amber B. Koehler, Amie Fonder, Susan M. Schwager, Susan L. Slager, Tait D. Shanafelt, Neil E. Kay, Sameer A. Parikh	2019	42
17	Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting Journal of Hematology & Oncology ·Jing-Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng, Delong Liu	2021	41
18	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice Cancer Medicine ·Sameer A. Parikh, Sara J. Achenbach, Timothy G. Call, Kari G. Rabe, Wei Ding, José F. Leis, Saad S. Kenderian, Asher Chanan‐Khan, Amber B. Koehler, Susan M. Schwager, Eli Muchtar, Amie Fonder, Kristen McCullough, Adrienne Nedved, Matthew D. Smith, Susan L. Slager, Neil E. Kay, Heidi D. Finnes, Tait D. Shanafelt	2020	39
19	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre British Journal of Haematology ·Paul J. Hampel, Melissa C. Larson, Brian Kabat, Timothy G. Call, Wei Ding, Saad S. Kenderian, Deborah A. Bowen, Justin C. Boysen, Susan M. Schwager, José F. Leis, Asher Chanan‐Khan, Eli Muchtar, Curtis A. Hanson, Susan L. Slager, Neil E. Kay, Kari G. Chaffee, Tait D. Shanafelt, Sameer A. Parikh	2018	38
20	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes Annals of Hematology ·William J. Archibald, Kari G. Rabe, Brian Kabat, Joerg Herrmann, Wei Ding, Neil E. Kay, Saad S. Kenderian, Eli Muchtar, José F. Leis, Yucai Wang, Asher Chanan‐Khan, Susan M. Schwager, Amber B. Koehler, Amie Fonder, Susan L. Slager, Tait D. Shanafelt, Timothy G. Call, Sameer A. Parikh	2020	35

About Wei Ding

Wei Ding is a scholar working on Genetics, Pathology and Forensic Medicine, Immunology, Pulmonary and Respiratory Medicine and Oncology, having authored 117 papers that have together received 2.2k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (100 papers), Lymphoma Diagnosis and Treatment (57 papers), Immunodeficiency and Autoimmune Disorders (28 papers), Advanced Breast Cancer Therapies (14 papers), Gastrointestinal Tumor Research and Treatment (9 papers), Chronic Myeloid Leukemia Treatments (8 papers), Acute Lymphoblastic Leukemia research (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). The work is most often cited by research in Genetics (1.7k citations), Pathology and Forensic Medicine (1.2k citations), Hematology (479 citations), Immunology (751 citations) and Gastroenterology (89 citations). Wei Ding has collaborated with scholars based in United States, China and Australia. Frequent co-authors include Neil E. Kay, Timothy G. Call, Tait D. Shanafelt, Susan M. Schwager, Susan L. Slager, Sameer A. Parikh, José F. Leis, Kari G. Rabe, Diane F. Jelinek and Clive S. Zent. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, American Journal of Hematology and Blood Cancer Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact